Non-Arteritic Ischemic Optic Neuropathy Following COVID-19 Vaccination in Korea: A Case Series.
Coronavirus Disease 2019 (COVID-19)
Non-Arteritic Anterior Ischemic Optic Neuropathy
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Vaccination
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
27 Mar 2023
27 Mar 2023
Historique:
received:
18
08
2022
accepted:
27
12
2022
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
To report the clinical manifestations of non-arteritic anterior ischemic optic neuropathy (NAION) cases after coronavirus disease 2019 (COVID-19) vaccination in Korea. This multicenter retrospective study included patients diagnosed with NAION within 42 days of COVID-19 vaccination. We collected data on vaccinations, demographic features, presence of vascular risk factors, ocular findings, and visual outcomes of patients with NAION. The study included 16 eyes of 14 patients (6 men, 8 women) with a mean age of 63.5 ± 9.1 (range, 43-77) years. The most common underlying disease was hypertension, accounting for 28.6% of patients with NAION. Seven patients (50.0%) had no vascular risk factors for NAION. The mean time from vaccination to onset was 13.8 ± 14.2 (range, 1-41) days. All 16 eyes had disc swelling at initial presentation, and 3 of them (18.8%) had peripapillary intraretinal and/or subretinal fluid with severe disc swelling. Peripapillary hemorrhage was found in 50% of the patients, and one (6.3%) patient had peripapillary cotton-wool spots. In eight fellow eyes for which we were able to review the fundus photographs, the horizontal cup/disc ratio was less than 0.25 in four eyes (50.0%). The mean visual acuity was logMAR 0.6 ± 0.7 at the initial presentation and logMAR 0.7 ± 0.8 at the final visit. Only 64% of patients with NAION after COVID-19 vaccination have known vascular and ocular risk factors relevant to ischemic optic neuropathy. This suggests that COVID-19 vaccination may increase the risk of NAION. However, overall clinical features and visual outcomes of the NAION patients after COVID-19 vaccination were similar to those of typical NAION.
Sections du résumé
BACKGROUND
BACKGROUND
To report the clinical manifestations of non-arteritic anterior ischemic optic neuropathy (NAION) cases after coronavirus disease 2019 (COVID-19) vaccination in Korea.
METHODS
METHODS
This multicenter retrospective study included patients diagnosed with NAION within 42 days of COVID-19 vaccination. We collected data on vaccinations, demographic features, presence of vascular risk factors, ocular findings, and visual outcomes of patients with NAION.
RESULTS
RESULTS
The study included 16 eyes of 14 patients (6 men, 8 women) with a mean age of 63.5 ± 9.1 (range, 43-77) years. The most common underlying disease was hypertension, accounting for 28.6% of patients with NAION. Seven patients (50.0%) had no vascular risk factors for NAION. The mean time from vaccination to onset was 13.8 ± 14.2 (range, 1-41) days. All 16 eyes had disc swelling at initial presentation, and 3 of them (18.8%) had peripapillary intraretinal and/or subretinal fluid with severe disc swelling. Peripapillary hemorrhage was found in 50% of the patients, and one (6.3%) patient had peripapillary cotton-wool spots. In eight fellow eyes for which we were able to review the fundus photographs, the horizontal cup/disc ratio was less than 0.25 in four eyes (50.0%). The mean visual acuity was logMAR 0.6 ± 0.7 at the initial presentation and logMAR 0.7 ± 0.8 at the final visit.
CONCLUSION
CONCLUSIONS
Only 64% of patients with NAION after COVID-19 vaccination have known vascular and ocular risk factors relevant to ischemic optic neuropathy. This suggests that COVID-19 vaccination may increase the risk of NAION. However, overall clinical features and visual outcomes of the NAION patients after COVID-19 vaccination were similar to those of typical NAION.
Identifiants
pubmed: 36974402
pii: 38.e95
doi: 10.3346/jkms.2023.38.e95
pmc: PMC10042731
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e95Informations de copyright
© 2023 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
JAMA. 2021 Oct 12;326(14):1390-1399
pubmed: 34477808
Arch Ophthalmol. 1996 Nov;114(11):1366-74
pubmed: 8906027
Vaccines (Basel). 2022 Feb 21;10(2):
pubmed: 35214800
Korean J Ophthalmol. 2022 Apr;36(2):168-170
pubmed: 35067014
Ann Neurol. 2022 Mar 2;:
pubmed: 35233819
Eye (Lond). 2010 Nov;24(11):1675-80
pubmed: 20689570
Ocul Immunol Inflamm. 2022 Jul;30(5):1218-1221
pubmed: 35113750
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835280
Am J Ophthalmol. 2022 Aug;240:79-98
pubmed: 35227700
Ophthalmology. 1987 Nov;94(11):1503-8
pubmed: 3684223
Control Clin Trials. 1998 Jun;19(3):276-96
pubmed: 9620811
Atherosclerosis. 2014 Dec;237(2):381-90
pubmed: 25463062
Rev Med Virol. 2022 Jul;32(4):e2327
pubmed: 35112763
J Neuroophthalmol. 2021 Dec 16;:
pubmed: 34924538
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Case Rep Ophthalmol. 2014 Aug 23;5(2):267-9
pubmed: 25298770
Vaccines (Basel). 2022 Oct 20;10(10):
pubmed: 36298623
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288
pubmed: 33630816
BMJ. 2021 Jun 23;373:n1343
pubmed: 34162598
J Clin Med. 2021 Dec 05;10(23):
pubmed: 34884407
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4286-4291
pubmed: 28846776
Korean J Ophthalmol. 2022 Feb;36(1):80-82
pubmed: 34823340
Circulation. 2005 Oct 4;112(14):2193-200
pubmed: 16186422
BMJ. 2021 Jun 14;373:n1435
pubmed: 35727911
J Neuroophthalmol. 1998 Mar;18(1):56-9
pubmed: 9532544
Prog Retin Eye Res. 2009 Jan;28(1):34-62
pubmed: 19063989
Oxf Open Immunol. 2021 May 22;2(1):iqab010
pubmed: 34522886
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Mol Ther. 2021 Sep 1;29(9):2794-2805
pubmed: 34365034
Hypertens Res. 2022 May;45(5):846-855
pubmed: 35273351
Ophthalmology. 2008 Dec;115(12):2275-81
pubmed: 19041480
Arch Ophthalmol. 2002 May;120(5):601-5
pubmed: 12003609
JAMA. 1995 Feb 22;273(8):625-32
pubmed: 7844872
Ophthalmol Ther. 2022 Feb;11(1):81-100
pubmed: 34914035